Sign inJoin waitlistJoin the waitlist

Bradley McGregor

Director of Clinical Research, Lank Center for Genitourinary Oncology · Mass General Brigham

Credentials: · · · ·

History

Lank Center for Genitourinary Oncology · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
San Antonio Uniformed Services Health Education Consortium
2007–2010
Internal Medicine
San Antonio Uniformed Services Health Education Consortium
2004–2007
Tufts University School of Medicine
2000–2004
Tufts University
1996–2000

Research

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Journal of Clinical Oncology · 2019 · 536 citations
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Cancer Cell · 2021 · 507 citations
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Cancer Cell · 2021 · 409 citations

Toni Choueiri
55 papers
GS
Guru Sonpavde
27 papers
Rana McKay
23 papers · 7 as a resident
Xiaolin Wei
22 papers · 3 as a resident
Sabina Signoretti
16 papers · 1 as a fellow
David Braun
15 papers
David McDermott
15 papers
LH
Lauren Harshman
15 papers
Praful Ravi
15 papers · 4 as a fellow
Stephanie Berg
14 papers
Sumanta Pal
14 papers
DH
Daniel Heng
13 papers

Clinical trials

Avelumab, Palbociclib and Axitinib in Advanced RCC
Principal investigator · Withdrawn · Phase 2
Bradley A. McGregor, MD
2024–2027
Sacituzumab Govitecan Plus EV in Metastatic UC
Principal investigator · Recruiting · Phase 1, Phase 2
Dana-Farber Cancer Institute
2021–2028
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Principal investigator · Active not recruiting · Phase 2
Bradley A. McGregor, MD
2020–2027
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Principal investigator · Withdrawn · Phase 2
Dana-Farber Cancer Institute
2019